Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midodrine for Refractory Ascites in Children with Cirrhosis
NCT05084534Withdrawn
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Nov 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of midodrine in ascites (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Proportion of patients with partial or complete control of ascites at 12 weeks. Planned start Nov 2021; status: withdrawn.
02
Drugs
midodrine
03
Conditions
ascites
Beyond the preview
Go deeper on NCT05084534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05084534.